The primary objective of the study is to determine the safety and tolerability of I-131-CLR1404, with and without concurrent weekly dexamethasone, in patients with relapsed or refractory multiple myeloma who have previously been treated with, or are intolerant of, an immunomodulator and a proteasome inhibitor.
SparkCures ID | 756 |
---|---|
Trial Phase | Phase 1 |
Enrollment | 33 Patients |
Treatments |
|
Tags |
|
Trial Sponsors |
|
NCT Identifier |
|
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
Inclusion Criteria:
Exclusion Criteria:
Please visit the ClinicalTrials.gov page for historical site information.
View CentersRead the latest news and updates on this trial.
October 01, 2019
February 02, 2019
Myeloma patients who had relapsed after receiving both a proteasome inhibitor (like Velcade) and immunomodulator (like Revlimid) participated in a Phase I study of a new drug called CLR 131 and experienced an average 22 month overall survival.